Manajemen Koagulopati pada Pasien Covid-19

Novita Anggraeni

Abstract

The 2019–20 Coronavirus outbreak has been declared a Public Health Emergency of International Concern (PHEIC). Cytokine storms and impaired blood coagulation are frequently associated with Covid-19. Dysregulation of the coagulation cascade and interalveolar fibrin clot formation are prominent findings in coronavirus infection associated with severe respiratory disease and have been demonstrated in human and animal models. A 66-year-old woman with COVID-19 was consulted by the Anesthesia Department of the Arifin Achmad Hospital Pekanbaru for intensive care. The patient complained of shortness of breath since 4 days of SMRS. The patient had an elevated d-dimer. Anticoagulation may be considered in COVID-19 patients from the time of treatment until the patient's discharge (35-42 days).

Keywords

anticoagulants, COVID-19, coagulopathy, D-Dimer, hypercoagulation

References

World Health Organization (WHO). Novel Coronavirus (2019-nCoV): situation report. Geneva; 2020.

Gorbalenya AE. Severe acute respiratory syndrome-related coronavirus – The species and its viruses, a statement of the Coronavirus Study Group. BioRxiv. 2020;2(7):93–7.

Centers for Disease Control and Prevention. 2019 Novel Coronavirus (2019-nCoV). Washington DC; 2020.

Hessen MT. Novel Coronavirus Information Center: Expert guidance and commentary. Else Connect. 2020;

Giannis D, Gianni P, Ziagos I. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol. 2020;127.

Menter T, Haslbauer JD, Nienhold R, Savic S, Hopfer H, Deigendesvh N et al. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. Histopathology. 2020;77(2):198–209.

Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients. Am J Roentgenol. Juli 2020;215(1):87–93.

Correa TD, Cordiolo RL, Guerra JCC, Da Silva BC, Rodrigues RR, Souza GM et al. Coagulation profile of COVID-19 patients admitted to the ICU: An exploratory study. PLoS One. 2020;15(12).

Long H, Nie L, Xiang X, Li H, Zhang X, Fu X et al. D-dimer and prothrombin time are the significant indicators of severe COVID-19 and poor prognosis. Hindawi Publ Corp. 2020;3(2).

Aggarwal M, Dass J, Mahapatra M. hemostatic abnormalities in COVID-19: an update. Indian J Hematol Blood Transfus. 2020;36(4):616–26.

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;

Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, Heinemann A et al. Autopsy findings and venous thromboembolism in patients with COVID-19: A prospective cohort study. Ann Intern Med. 2020;173(4):268–77.

Abou-Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L. The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. Thromb Res. 2020;194:101–15.

Hajra A, Mathai SV, Ball S, Bandyopadhyay D, Veyseh M, Chakraborty S et al. management of thrombotic complications in COVID-19: An Update. Drugs. 2020;80:1553–62.

DOI: https://doi.org/10.26891/JIK.v15i2.2021.100-103

Refbacks

  • There are currently no refbacks.